Shengda Bio-pharm discloses latest status of two projects, and expects losses in FY2023

Summary: In a 19 Jan. response to SSE's Letter of Inquiry, Shengda Bio-pharm disclosed the latest status of two projects to be financed by non-public share issuance. Also, on 31 Jan., the company posted estimated results for 2023.On 19 Jan., Zhejiang...

Vitamins China E-News 202402

www.cnchemicals.com